Will reducing the dose of Olaparib affect its efficacy?

Patients with BRCA1/-mutated, platinum-sensitive, recurrent ovarian cancer who required a reduction or interruption of olaparib (Olaparib) treatment during the first 12 weeks of treatment had no worse survival outcomes than patients who received the recommended dose, according to auxiliary findings from the SOLO2 study. These data suggest that patients who require a change in their PARP inhibitor therapy due to adverse events (AEs) will not be negatively affected. Following a single dose of olaparib of 25 mg to 45 mg (0.08 to 1.5 times the recommended dose), the area under the curve (AUC) of olaparib increased approximately proportionally, and the increase in maximum concentration (Cmax) was slightly less than the proportional increase over the same dose range. Reducing the dose of olaparib may not affect the efficacy of the drug, but patients cannot reduce the dose on their own and must do so under the guidance of a doctor.